BRANFORD, Conn., Feb. 9 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that Frank M. Armstrong, M.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 13, 2007, at 3:00 p.m. Eastern time.
Access to a live webcast of the presentation will be available at http://www.curagen.com. A replay of the webcast will be accessible beginning one hour after the presentation and available on the Company's website until March 13, 2007.
About CuraGen
CuraGen Corporation is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, and small molecule therapeutics, that aim to offer hope for patients with cancer, inflammatory diseases, and diabetes. CuraGen's strategic alliances have resulted in a deep pipeline of potential therapeutics that is being developed by the Company's experienced research and development teams. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference in the lives of patients by bringing forward promising therapeutics that address unmet medical needs. To further capitalize on CuraGen's extensive research and development expertise, CuraGen founded a majority-owned subsidiary, 454 Life Sciences, which has developed and is commercializing advanced technologies for the sequencing of DNA. CuraGen is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.
CuraGen Contact: Glenn Schulman, Pharm.D. Director of Investor Relations gschulman@curagen.com (888) 436-6642 CRGN-G
CuraGen CorporationCONTACT: Glenn Schulman, Pharm.D., of CuraGen Corporation,+1-888-436-6642, or gschulman@curagen.com
Web site: http://www.curagen.com/
